Lifted Regulatory Overhang Raises Cadila’s Value
Cadila Healthcare, the listed flagship of billionaire Pankaj Patel’s Zydus Group, has become India’s second most valuable pharmaceutical firm after its shares were lifted by the resolution of US regulatory issues engulfing its biggest manufacturing plant, and a string of drug approvals.
You may also be interested in...
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.